Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib for recurrent anaplastic oligodendroglioma/oligoastrocytoma (RB-positive)
2015-001722-42Phase 2Active
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in anaplastic oligodendroglioma (AO) and oligoastrocytoma, sponsored by Grupo Español de Investigación en Neurooncología. Primary endpoint: Progression-free survival at 6 months. Started Jun 2015; status: active.
02
Drugs
palbociclib
03
Conditions
anaplastic oligodendroglioma (AO)oligoastrocytoma
Beyond the preview
Go deeper on 2015-001722-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001722-42.